Effective drug discovery and development rely heavily on the availability of predictive pre-clinical models. For decades, target-based drug discovery has focused on immortalised cells to identify and optimise inhibitory or activating molecules. Elena Matsa at Discovery Technology examines automated
identification of cardiac hypertrophy modulators using a hipsc-derived disease model.